2025-02-11 - Analysis Report
## UnitedHealth Group Inc. (UNH) Stock Review

**0. Summary Statistics:**

* **Ticker:** UNH
* **Company:** UnitedHealth Group Inc., a diversified healthcare company.
* **Cumulative Return (UNH):** 144.796%
* **Cumulative Return (VOO):** 120.049%
* **Return Difference (UNH - VOO):** 24.7%
* **Relative Divergence (vs. VOO):** 20.7% (indicates UNH's performance is in the upper 20th percentile of its historical performance relative to VOO).


**1. Performance Comparison & Alpha/Beta Analysis:**

UNH has significantly outperformed the S&P 500 (VOO) over the period analyzed, with a cumulative return 24.7% higher.  The relative divergence metric suggests this outperformance is relatively high compared to its historical performance against the S&P 500.

The provided Alpha/Beta analysis shows consistently positive alpha across various periods (0.1 to 0.3), indicating UNH has generated returns above what would be expected based solely on its beta (market risk).  Beta values fluctuate, generally hovering around 0.1-0.3.  The high CAGR (Compound Annual Growth Rate) in several periods (e.g., 96% from 2019-2021) further highlights its strong performance. Note the negative CAGR in 2022-2024 and 2023-2025 which might warrant further investigation.  Market cap consistently increased over the years.

**2. Recent Price Movement:**

* **Closing Price:** $533.37
* **5-Day Moving Average:** $535.14
* **20-Day Moving Average:** $534.58
* **60-Day Moving Average:** $545.05

The stock price is currently trading below its 5 and 20-day moving averages, suggesting a short-term bearish trend.  It's also below the 60-day moving average, suggesting a longer-term bearish trend.  The recent price change shows a small increase compared to the previous close, indicating slight upward pressure.

**3. Technical Indicators & Expected Return:**

* **RSI:** 55.36 (slightly above neutral; neither overbought nor oversold)
* **PPO:** -0.0214 (slightly negative, suggesting a weak bearish momentum)
* **Delta Relative Divergence (20-day):** -6.7% (short-term bearish divergence)
* **Expected Return (Long-Term):** 301.7% (This represents a significant projected outperformance compared to the S&P 500 over a 2+ year horizon. This is a high expectation and should be treated with caution).  The recent price change is minor, suggesting the current price movement doesn't reflect significant market events.

**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue       |
|------------|--------|---------------|
| 2024-11-04 | 6.56   | $100.82B      |
| 2024-08-09 | 4.58   | $98.86B      |
| 2024-05-09 | -1.53  | $99.80B      |
| 2023-11-06 | 6.31   | $92.36B      |
| 2024-11-04 | 6.31   | $92.36B      |

There appears to be a duplicate entry for 2024-11-04. Revenue is consistently high. EPS shows variability, with a significant negative EPS in Q2 2024.  Further investigation is needed to understand the reasons behind this fluctuation.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue    | Profit Margin |
|---------|------------|---------------|
| 2024-09-30 | $99.18B   | 21.56%        |
| 2024-06-30 | $97.86B   | 21.52%        |
| 2024-03-31 | $98.78B   | 22.26%        |
| 2023-12-31 | $93.25B   | 22.33%        |
| 2023-09-30 | $91.36B   | 24.51%        |

Revenue remains relatively stable and high. Profit margins are generally strong, though slightly decreased in recent quarters.


**Capital and Profitability:**

| Quarter | Equity     | ROE      |
|---------|------------|----------|
| 2024-09-30 | $94.53B   | 6.41%    |
| 2024-06-30 | $89.36B   | 4.72%    |
| 2024-03-31 | $86.69B   | -1.63%   |
| 2023-12-31 | $88.76B   | 6.15%    |
| 2023-09-30 | $84.49B   | 6.91%    |

Equity shows a general upward trend.  ROE is volatile, reflecting the variability in profitability. The negative ROE in Q1 2024 is concerning and requires further investigation.

**6. Overall Analysis:**

UNH has demonstrated strong historical outperformance against the S&P 500.  However, recent price action shows a bearish trend, and some financial metrics (Q2 2024 EPS and ROE) raise concerns. The high projected long-term expected return should be approached cautiously due to the inherent uncertainty in such projections.  Further research is needed to determine if the negative performance of 2024 is a temporary blip or a sign of larger shifts in the healthcare landscape.  A detailed analysis of the reasons behind the negative EPS and ROE in Q1 and Q2 2024 is crucial before making any investment decisions.  The significant fluctuation in the key metrics requires a deeper understanding of the underlying business factors.
